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Purpose: This research was conducted to assess the biocompatibility of the core–shell Fe3O4@
Au composite magnetic nanoparticles (MNPs), which have potential application in tumor 
hyperthermia.
Methods: Fe3O4@Au composite MNPs with core–shell structure were synthesized by reduction 
of Au3+ in the presence of Fe3O4-MNPs prepared by improved co-precipitation. Cytotoxicity 
assay, hemolysis test, micronucleus (MN) assay, and detection of acute toxicity in mice and 
beagle dogs were then carried out.
Results: The result of cytotoxicity assay showed that the toxicity grade of this material on 
mouse fibroblast cell line (L-929) was classified as grade 1, which belongs to no   cytotoxicity. 
Hemolysis rates showed 0.278%, 0.232%, and 0.197%, far less than 5%, after treatment 
with different concentrations of Fe3O4@Au composite MNPs. In the MN assay, there was no 
significant difference in MN formation rates between the experimental groups and negative 
control (P . 0.05), but there was a significant difference between the experimental groups and 
the positive control (P , 0.05). The median lethal dose of the Fe3O4@Au composite MNPs 
after intraperitoneal administration in mice was 8.39 g/kg, and the 95% confidence interval was 
6.58–10.72 g/kg, suggesting that these nanoparticles have a wide safety margin. Acute toxicity 
testing in beagle dogs also showed no significant difference in body weight between the treat-
ment groups at 1, 2, 3, and 4 weeks after liver injection and no behavioral changes. Furthermore, 
blood parameters, autopsy, and histopathological studies in the experimental group showed no 
significant difference compared with the control group.
Conclusion: The results indicate that Fe3O4@Au composite MNPs appear to be highly biocom-
patible and safe nanoparticles that are suitable for further application in tumor hyperthermia.
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Introduction
In the past two decades, the development and implementation of innovative processes in 
the field of tumor hyperthermia were being extensively studied because of the innova-
tion of biomedical nanomaterials. Many efforts have been made to design appropriate 
nanoparticles and nanocomposites for hyperthermia.1,2 Based on the development 
of composite nanoparticles, core–shell superparamagnetic particles have attracted a 
broader interest because of their combined advantages of the   heteromaterials. Among 
them, the applications of gold-coated iron oxide nanoparticles are of particular 
interest because they have not only the magnetism of iron oxide that renders them 
easily manipulated and heated by an external magnetic field, but also the excellent 
near-infrared (NIR) light sensitivity and strong adsorptive ability of the Au layer can International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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make them useful in photothermal therapy.3–5 However, it 
should be noted that, while a considerable number of stud-
ies have been done on the synthesis and coating process of 
gold-coated iron oxide nanoparticles, attention devoted to 
the biocompatibility for in-vivo biomedical applications to 
ensure their safe clinical use of this kind of heteromaterial is 
still limited. The basic criteria for their clinical application are 
safety and good biocompatibility, which are also important 
to the industrialization of nanomedicine.6,7
The present authors’ earlier research has shown that Fe2O3 
and Fe3O4 magnetic nanoparticles (MNPs) achieve a satis-
factory thermal therapeutic effect on cell lines and animal 
models of liver cancer and cervical cancer in magnetic fluid 
hyperthermia (MFH), without histological toxicity to non-
target organs or tissues.8,9 Furthermore, in this present study 
highly crystalline, monodispersed core–shell multifunctional 
Fe3O4@Au composite MNPs were synthesized and used in 
MFH combined with NIR hyperthermia. The formation of 
the core–shell structure was achieved in two consecutive 
steps, seeding the Fe3O4 core followed by coating the gold 
shell. Well engineered Fe3O4@Au composite MNPs tend 
to accumulate in the tumor due to the unorganized nature 
of malignancy vasculature when they are injected into an 
organ with a tumor, and they have strong responsiveness 
and low heating effect under alternating magnetic field and 
NIR laser exposure, which can effectively guide heat to the 
tumor without damaging the normal tissue.5 Although gold is 
an inert metal, the effect on normal cell proliferation cannot 
be underestimated. Moreover, the nature of the composite 
nanoparticles could remarkably affect their biocompatibility. 
Thus, the toxicity and biocompatibility of the complex in 
vitro and in vivo need to be thoroughly evaluated before the 
material can be applied in hyperthermia research.10 There-
fore, the cytotoxicity assay, hemolysis test, micronucleus 
(MN) assay, and detection of acute toxicity in mice and 
beagle dogs were introduced to evaluate the biocompatibil-
ity of self-assembled Fe3O4@Au composite MNPs in this   
research.11,12
Materials and methods
Main apparatus and reagents
The transmission electron microscope (TEM) used was an 
H-600 model (Hitachi, Tokyo, Japan), and the scanning 
electron microscope (SEM) was a JSM-6360 model (JEOL 
Ltd, Akishima, Japan). The energy dispersive spectro  meter 
(EDS) was purchased from Thermo NORAN Vantage 
(Waltham, MA). The laser particle size analyzer and zeta 
potential analyzer were purchased from Malvern Instruments 
Ltd (Worcestershire, UK). A 752 prismatic ultraviolet-visible 
(UV-vis) spectrophotometer was purchased from Shanghai 
Precision Scientific Instrument Co, Ltd, (Shanghai, China). 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) and dimethyl sulfoxide were obtained from 
Sigma-Aldrich (St Louis, MO). RPMI-1640 medium was 
purchased from Gibco-Invitrogen Corp (Carlsbad, CA). 
Other reagents included ferric chloride, ferrous sulfate, 
and ammonia water (Hanguang Chemical Reagent Co, Ltd, 
Shanghai, China), HAuCl4, NH2OH3HCl, and potassium 
oxalate (Shanghai First Reagent Factory, Shanghai, China), 
newborn calf serum (Si-Ji-Qing the Biotechnology Co, Ltd, 
Hangzhou, China), methanol (Zhenxing First Chemical Fac-
tory, Shanghai, China), cyclophosphamide (CTX) (Jiangsu 
Hengrui Medicine Co Ltd, Lianyungang, China), and Giemsa 
staining solution (Chroma, Bellows Falls, VT). All reagents 
were of analytical grade.
Cells and animals
Cell line L-929 was purchased from Shanghai Institute 
of Cell Biology (Shanghai, China). Kunming albino mice, 
age matched (6 weeks of age) and weight matched (18–22 g), 
New Zealand rabbits weight matched (2.5 kg), and beagle 
dogs, age matched (6–8 months of age) and weight matched 
(7–9 kg), were provided by the experimental animal center 
of Yangzhou University (Yangzhou, China). All animal 
experiments were evaluated and approved by the Animal and 
Ethics Review Committee of Southeast University (Nanjing, 
Jiangsu Province, China). All animals were maintained in a 
pathogen-free, air-conditioned environment at 24°C ± 2°C 
with a standard 12-hour light/12-hour dark cycle. The animals 
were allowed free access to tap water and food in the form 
of a standard pellet diet.
Preparation and characterization  
of Fe3O4@Au composite MNPs
Fe3O4-MNPs were prepared by the technique of chemical co-
precipitation as previously published.9 Fe3O4@Au core–shell 
composite nanoparticles were then synthesized by reduction 
of Au3+ in the presence of Fe3O4-MNPs, seeding the Fe3O4 
core, followed by coating the gold shell. The operating 
procedure adopted was the following. First, the Fe3O4-MNP 
solution was diluted to 10 mM in deionized water, and 
20 mL was stirred with 20 mL of 1 M sodium citrate for 
10 minutes. Next, the solution was diluted with deionized 
water to 200 mL, and 1 mL of NH2OH3HCl solution of 1 M 
was added. Then, 1% HAuCl4 (10 mL) was incrementally 
added dropwise with stirring. A total of three additions (each International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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for NH2OH3HCl and HAuCl4) were performed during the 
reaction, and the stirring continued for at least 30 minutes 
after each addition. The clear black solution became brown 
at first addition and changed to garnet after three iterative 
additions. TEM and SEM were used to observe the mor-
phological characteristics of Fe3O4@Au composite MNPs. 
Meanwhile, EDS was employed to assay their composition. 
A laser particle size analyzer and a zeta potential analyzer 
were used to detect their average diameter and zeta potential. 
In addition, the UV-vis spectra were acquired with a UV-vis 
spectrophotometer, and the magnetization was measured by 
a vibrating sample magnetometer integrated in a physical 
property measurement system (PPMS-9; Quantum Design, 
San Diego, CA) up to 5000 Oe at 300 K.
The cytotoxicity of Fe3O4@Au  
composite MNPs
MTT assay was used to evaluate cell toxicity.13 The sterile 
nanoparticles were diffused at 100 mg/mL concentration 
in RPMI-1640 medium (containing 10% fetal calf serum) 
for 72 hours at 37°C. After centrifugation at 2500 rpm for 
5 minutes, the supernatant was filtered to get leaching liquor 
of 100% concentration. L929 fibroblast cells were seeded in 
96-well plates (6000 cells per well) for 24 hours in RPMI-
1640 medium. Then they were divided into six groups (eight 
wells per group) and incubated with various concentrations of 
leaching liquor (100%, 75%, 50%, and 25% leaching liquor), 
RPMI-1640 medium containing 10% fetal calf serum (nega-
tive control) and 0.7% polyacrylamide (positive control) for 
48 hours. Inverted microscopy was used to observe general 
morphological changes of the L929 cells, and then the MTT 
assay was performed and the optical density (OD) values were 
measured at 492 nm. The cell relative growth rate (RGR) was 
calculated as follows:
  OD of experimental group
RGR =
OD of negative control group
  (1)
The toxicity grade is precise when the experimental 
results show grade 0 and grade 1. If the results show grade 
2, the toxicity should be evaluated by both RGR and the mor-
phological changes of cultured cells. The toxicity is uncertain 
when the results belong to other grades (Table 1).
Hemolysis test of Fe3O4@Au  
composite MNPs
Blood was obtained from healthy New Zealand rabbits 
and anticoagulated with potassium oxalate, at a final 
concentration of 1.0 mg/mL of blood. The Fe3O4@Au com-
posite MNPs were rinsed three times with distilled water, 
lixiviated with 0.9% saline, with a final concentration reached 
of 100 mg/mL. 0.9% saline and distilled water were used as 
the negative control (0% hemolysis) and the positive control 
(100% hemolysis), respectively. The material detected was 
divided into three concentration groups, ie, 100, 75, and 
50 mg/mL. Each group contained three test tubes, each of 
which contained either 10 mL leaching liquor of the mate-
rial, 0.9% saline, or distilled water. Then, 0.2 mL of diluted 
anticoagulated blood was added to each tube preheated for 
30 minutes at 37°C. After incubation for 60 minutes at 37°C, 
the tubes were centrifugated at 2500 rpm for 5 minutes. 
Next, the supernatant fluid was assembled, and OD values 
were measured at 545 nm by UV-vis spectrophotometry. The 
hemolysis rate (HR) was calculated using the mean OD value 
for each group as follows:
  HR (%) = (Dt - Dnc)/(Dpc - Dnc) × 100%,  (2)
where Dt is the absorbance of the testing sample, and Dpc and 
Dnc are the absorbance of the positive control and the negative 
control, respectively.14,15
MN assay of Fe3O4@Au composite  
MNPs
The KunMing albino mice (20–22 g) were randomly 
divided into six groups; there were five females and five 
males in every group. The animals were then treated with 
100 mg/mL Fe3O4@Au composite MNPs (5.00, 3.75, 2.50, and 
1.25 g/kg), 0.9% saline (as negative group) and CTX 40 mg/kg 
(as positive group) respectively. All experimental mice were 
injected intraperitoneally twice, with a 24-hour interval, 
and then sacrificed 6 hours after the second   administration. 
The thighbone marrows were extracted for smears, immo-
bilized 5 minutes with methanol, and then stained with 
Giemsa for 15 minutes. At least 1000 polychromatic 
erythrocytes (PEC) were counted for each mouse, and the 
rate of formation of PEC containing MN was calculated. 
Table 1 RGR and toxicity grade conversion
Toxicity grade RGR
Grade 0 $1
Grade 1 0.75–0.99
Grade 2 0.50–0.74
Grade 3 0.25–0.49
Grade 4 0.01–0.24
Grade 5 0
Abbreviation: RGR, relative growth rate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Poisson distribution was used to analyze statistic difference 
between each group.16
Acute toxicity testing in mice
The KunMing albino mice were randomly assigned into 
eight groups, with five females and five males in each 
group. Fe3O4@Au composite MNPs dissolved in 0.9% 
saline with a concentration of 100 mg/mL were injected 
intraperitoneally into the mice at dosages of 1.77, 2.51, 
3.54, 5.00, 7.06, 9.98, 14.09, and 19.89 g/kg. The gen-
eral behavior of the mice was observed continuously for 
1 hour immediately after injections and then intermittently 
observed for a period of 24 hours. All mice were further 
observed for up to 14 days after treatment, and general 
physical states, including respiration, eating, and move-
ment were monitored. Any signs of toxicity and deaths 
were recorded. Median lethal dose (LD50) was evaluated 
by the Karber method.17 The animals were executed after 
the examination was finished.
Acute toxicity studies in beagle dogs
The animals were randomly divided into two groups: one 
experimental group and one control group, with three males 
and three females in each group. Normal parameters includ-
ing body weight, temperature, appetite, and performance 
of the dogs were observed and recorded before Fe3O4@Au 
composite MNPs treatment. Fe3O4@Au composite MNPs 
dissolved in 0.9% saline with the concentration of 100 mg/mL 
were administered via liver injection at a dosage of 0.1 g/kg. 
The control group was injected with the same volume of 0.9% 
saline. The rate of injection was kept constant (1 mL/min) 
during each treatment. All animals were carefully observed 
for an additional 4 weeks, with necessary food and water 
supply. Various parameters were measured and compared 
with the values obtained prior to treatment. All animals 
were then euthanized and various parameters determined 
after 4 weeks.
Body general parameters
All animals were weighed once every week. The objective 
signs, including cleanliness, behavior, and food intake were 
recorded every day.
Blood analysis
Blood samples were collected from the veins of the animals 
before administration and every week up to 4 weeks after 
treatment. The pertinent blood indices were determined with 
routine methods and an autoanalyzer.18
Autopsy study
Four weeks after administration, all animals were sacrificed 
by exsanguination and dissection. During the process of dis-
secting, the parenchymatous organs’ color, texture, and lumps 
were carefully examined. In the meantime, the weight of the 
heart, liver, spleen, lung, kidney, and brain were measured and 
recorded. The organ–body index was calculated according 
to the following formula:19
Organ–body weight index (%)  
  = Wet organ weight/Body weight × 100%  (3)
Histopathological study
Small organ pieces (3–5 mm thick) were fixed in 10% formal-
saline (0.9% saline in 10% formaldehyde) for 24 hours and 
washed in running water for another 24 hours. Samples were 
dehydrated by passing through 50%, 70%, 90%, and 100% 
alcohol over a 2-day period, and then cleared in benzene to 
remove alcohol until the tissues became transparent. This was 
followed by staining with hematoxylin-eosin and thorough 
examination using a light microscope.20,21
Statistical analysis
Data were analyzed using SPSS Statistics (v 11.5; IBM 
Corporation, Somers, NY) software. The statistical signifi-
cance of differences in mean values between the groups was 
analyzed using one-way analysis of variance. P-values ,0.05 
were considered statistically significant.
Results
Characterization of Fe3O4@Au 
composite MNPs
The self-prepared Fe3O4@Au composite MNPs were approxi-
mately spherical, high electron-dense, and uniform in size as 
observed by TEM and SEM (Figure 1A and B). Meanwhile, 
EDS confirmed that the prepared nanoparticles contained 
the elements of Fe, Au, and O (Figure 1B inset). The average 
diameter detected by Malvern laser particle size analyzer 
was about 35 nm, with a narrow diameter distribution for 
Fe3O4@Au composite MNPs (Figure 1C) and about 20 nm 
for Fe3O4-MNPs (Figure 1C inset). And the zeta potential of 
Fe3O4@Au composite MNPs at pH 7.4 was -23.2 ± 1.8 mV 
(Figure 1D) compared with the zeta potential value of 
-3.6 ± 1.8 mV for Fe3O4-MNPs (Figure 1D inset). Moreover, 
the UV-vis absorption spectra of Fe3O4@Au composite MNPs 
indicated 612 nm of the absorption peak (Figure 1E, curve 
b), while the Fe3O4-MNPs absorption spectra were increased 
with the wavelength decrease in the range 900–300 nm International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 1 Characterization of Fe3O4@Au composite MNPs. (A) Transmission electron microscopy image; (B) scanning electron microscopy image and energy dispersive 
spectrometry (inset); (C) the average diameter of Fe3O4@Au composite MNPs and Fe3O4-MNPs (inset); (D) the zeta potential of Fe3O4@Au composite MNPs and 
Fe3O4-MNPs (inset); (E) ultraviolet-visible absorption spectra of Fe3O4@Au composite MNPs (curve b) and Fe3O4-MNPs (curve a); and (F) hysteresis loops of Fe3O4@Au 
composite MNPs (curve b) and Fe3O4-MNPs (curve a). 
Abbreviation: MNPs, magnetic nanoparticles.
(Figure 1E, curve a). The magnetic hysteresis loops mea-
sured at 300 K showed that the saturation magnetization 
(Ms) value of Fe3O4-MNPs was 75.5 emu/g (Figure 1F, curve 
a), while the value of Fe3O4@Au MNPs was 51.8 emu/g   
(Figure 1F, curve b).
The cytotoxicity of Fe3O4@Au 
composite MNPs
The morphological changes of L929 cells after treatment 
with different concentrations of Fe3O4@Au composite MNPs 
leaching liquor were observed by inverted microscopy. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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As shown in Figure 2B–E, the shapes and growth of the 
treated cells were similar to those of cells in the negative 
group (Figure 2A). They exhibited normal features, such as 
clear edges, homogeneous staining, and no cell fragments, 
while the cells of the positive group became small and 
globular, and even parts of cells were suspended 48 hours 
later (Figure 2F). Only small amounts of cells survived. The 
results of the MTT assay are shown in Figure 3. According 
to RGR and toxicity grade conversion table (see Table 1), 
the toxicity of Fe3O4@Au composite MNPs leaching liquor 
was classified as grade 1, which is safe to the cells. This was 
in agreement with the findings from inverted microscopy 
and demonstrated that Fe3O4@Au composite MNPs did not 
show cytotoxicity in vitro.
Hemolysis experimental results  
of Fe3O4@Au composite MNPs
The hemolysis rates at 545 nm are listed in Table 2 for each 
experimental group. Hemolysis rates at the different con-
centrations of Fe3O4@Au composite MNPs were 0.278%, 
0.232%, and 0.197%, respectively, far less than 5%, which 
is the threshold for a hemolytic reaction.14
MN results of Fe3O4@Au composite 
MNPs
In this study, the MN formation rates of 5.00, 3.75, 2.50, 
and 1.25 g/kg experimental groups, negative control group, 
and positive control group were 2.5‰, 2.7‰, 2.6‰, 2.3‰, 
2.1‰, and 26.2‰ respectively (Figure 4), showing a sig-
nificant difference between the experimental groups and 
the positive control group (P , 0.05). But MN formation 
rates at different doses of experimental groups showed no 
statistical difference compared with the negative control 
group (P . 0.05).
Acute toxicity in mice
Some behavioral changes such as crouching, sluggishness, 
bradypnea, and slow response to external stimuli were 
observed among some animals immediately after Fe3O4@Au 
composite MNP administration. However, some resumed nor-
mal activity about 2 hours after the treatment. Interestingly, 
Fe3O4@Au composite MNP administration of 1.77 g/kg did 
not bring any notable changes to the animals. The deaths of 
most mice occurred during the first day after administration 
(Table 3). Mortality rates in the treatment groups were used 
to calculate the LD50 of Fe3O4@Au composite MNPs, which 
evaluate short-term toxicity after intraperitoneal administra-
tion. The LD50 of the material to the mice was 8.39 g/kg, and 
its 95% confidence interval (CI) was 6.58–10.72 g/kg from 
the acute toxicological study.
Acute toxicity in beagle dogs
Effect of Fe3O4@Au composite MNPs  
on the general behavior
The acute general toxicity test was used to evaluate short-
term toxicity after liver administration. Behavioral changes 
including slobbering, astasia, instability of gait, convul-
sion, anepithymia, and respiratory depression were not 
observed among animals in the experimental group. Both 
control group and experimental group animals displayed 
normal physical behavior during the 4-week observation 
period. All animals were weighed once a week. There was 
ABC
E F D
Figure 2 Morphology analysis of L929 cells incubated at different concentrations of Fe3O4@Au composite magnetic nanoparticles leaching liquor. (A) Negative control; (B) 
25% leaching liquor; (C) 50% leaching liquor; (D) 75% leaching liquor; (E) 100% leaching liquor; and (F) positive control. 
Note: Inverted microscopy, ×100 magnification.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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no significant difference in body weight values of beagle 
dogs between the experimental group and the control group 
(P . 0.05; Figure 5).
Effect of Fe3O4@Au composite MNPs on the 
biochemical and hematological parameters
The effect of liver injection of Fe3O4@Au composite MNPs 
on alanine aminotransferase (ALT), aspartic acid aminotrans-
ferase (AST), blood urea nitrogen (BUN), and creatinine 
(Cr) are presented in Figures 6 and 7, showing no significant 
differences between the experimental group and the control 
group in the data of ALT, AST, BUN, and Cr during the 
4 weeks (P . 0.05). Furthermore, no significant differences 
were observed for hematological parameters between the 
experimental group and the control group (P . 0.05; detailed 
data can be seen in Table S1).
Effect of Fe3O4@Au composite MNPs on the organs
The autopsy study was carried out 4 weeks after the animals 
were treated with Fe3O4@Au composite MNPs. The organs, 
including heart, liver, spleen, lung, kidney, brain, adrenal 
glands, and pancreas, were carefully examined and investi-
gated. No noticeable pathological changes such as swelling, 
shrinking, nodules, collapse, hard texture, and thickened 
capsule could be observed by the naked eye. No significant 
differences in organ weight or organ–body weight indices 
were found between the experimental group and the control 
group (P . 0.05; Figure 8).
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Figure 3 The MTT results of Fe3O4@Au composite magnetic nanoparticles. 
Notes: n = 8, mean ± standard deviation. The RGR of L929 cells incubated with 25%, 50%, 75%, and 100% leaching liquor were 0.977, 0.872, 0.849, and 0.826, respectively, 
which all classified as toxicity grade 1.
Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OD, optical density; RGR, relative growth rate.
Table 2   Hemolysis  test  of  Fe3O4@Au  composite  magnetic 
nanoparticles
Groups OD HR (%)
Negative control 0.0143 ± 0.002 –
100 mg/mL Fe3O4@Au 0.0167 ± 0.003 0.278
75 mg/mL Fe3O4@Au 0.0163 ± 0.001 0.232
50 mg/mL Fe3O4@Au 0.0160 ± 0.004 0.197
Positive control 0.8762 ± 0.012 –
Note: n = 3, mean ± standard deviation.
Abbreviations: OD, optical density; HR, hemolysis rate.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Effect of Fe3O4@Au composite MNPs  
on histopathological changes
Histopathological investigation was performed after the 
autopsy study. From the histological sections (Figure 9A), 
no significant pathological changes were detected in the 
liver tissue of experimental dogs, except for lots of Fe3O4@
Au composite MNPs taken up by cells around the needle 
passage and a small area of mechanical damage. Other 
organs including heart, spleen, lung, kidney, and brain 
showed no sign of pathological changes such as edema, 
atrophy, steatosis, liquefaction necrosis, hyalinization, 
calcification, and hemosiderosis compared with the cor-
responding organs from the dogs in the control group 
(Figure 9B–F).
Discussion
Recently, the unique structure and magnetic-optical 
  properties of Fe3O4@Au composite MNPs have made them 
promising materials for a wide range of biological applica-
tions such as cell labeling, tracking, imaging, gene delivering, 
and sensing. Particularly, there are potential applications in 
the intracellular/interstitial MFH and NIR hyperthermia.22–25 
However, there is concern about the potential toxicological 
effects of them in vitro and in vivo. At present, it is widely 
recognized that Fe3O4-MNPs are metabolized, stored, and 
transported through human tissues by proteins including 
ferritin, transferritin, hemosiderin, and others, such that 
the resultant iron is incorporated into the iron pool. Many 
researchers have synthesized Fe3O4-MNPs successfully with 
satisfactory biocompatibility and explored their biomedical 
applications.26–28 On the other hand, some researchers reported 
that bare Fe3O4-MNPs induced the formation of free hydroxyl 
radical species that reacted with intracellular constituents 
such as the cell’s endogenous DNA, thus inhibiting cellular 
function and proliferation.29,30 Moreover, it was found that 
exposure to dextran- or citric acid-coated Fe3O4-MNPs, of an 
approximate size of 31–38 nm, resulted in a dose-dependent 
decrease of HUVEC viability in vitro.31 These results confirm 
that the toxicity of Fe3O4-MNPs affect the biocompatibility 
and biosafety in vitro. Meanwhile, it was reported that the 
gold shell coating on the Fe3O4-MNPs surface improved the 
biocompatibility for cellular application, particularly at high 
magnetite loading. The improved biocompatibility may be 
attributed to the presence of gold shells which prevents the 
leaching of iron in acidic intracellular degradation process.32 
Similarly, the protective properties of the gold coating 
have also been reported by others.33 However, the literature 
also reported conflicting data regarding the cytotoxicity of 
Table 3 The results of acute toxicity testing of Fe3O4@Au composite MNPs
Group Dosage n Death number Death rate (p) Survival rate (q) p × q
g ⋅ kg-1 Logarithm
1 1.77 0.249 10 0 0 1.0 0
2 2.51 0.399 10 0 0 1.0 0
3 3.54 0.549 10 2 0.2 0.8 0.16
4 5.00 0.699 10 2 0.2 0.8 0.16
5 7.06 0.849 10 4 0.4 0.6 0.24
6 9.98 0.999 10 5 0.5 0.5 0.25
7 14.09 1.149 10 7 0.7 0.3 0.21
8 19.89 1.299 10 10 1.0 0 0
i = 0.15 ∑p = 3.0
Notes: lg LD50 = Xk - I(∑p - 0.5) = 1.299 - 0.15 (3.0 - 0.5) = 0.924; sm = i × (∑pq/n)1/2 = 0.15 × 0.36 = 0.054; lg LD50 and its 95% CI were 0.924 ± 1.96 × 0.054 = 0.924 ± 
0.106; LD50 and its 95% CI were 8.39 g/kg (6.58–10.72 g/kg). 
Abbreviations: LD50, median lethal dose; MNPs, magnetic nanoparticles.
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Figure 6 Liver function of beagle dogs in 4-week toxicity study of Fe3O4@Au composite MNPs.  
Notes: n = 6, mean ± standard deviation. ALT and AST of the experimental group administered with Fe3O4@Au composite MNPs showed no significant difference compared 
with the control group (P . 0.05). 
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gold nanoparticles in vitro. For example, some researchers 
demonstrated that different sized gold nanoparticles with 
varying surface chemistries were not toxic to human cells.34 
But others reported that gold nanoparticles demonstrated a 
size-dependent toxicity for sizes ranging from 0.8–15 nm.35 
Moreover, it was discovered that the electrical charge of the 
nanoparticle played a key role in determining toxicity, with 
cationic gold nanoparticles displaying moderate toxicity, 
while their anionic counterparts exhibited no toxic effects.36 
Interestingly, Alkilany et al reported that gold nanoparticles 
bore the same effective charge in the biological media 
because serum proteins adsorbed to gold nanoparticles, 
regardless of the initial surface charge, suggesting that 
physiochemical surface properties of nanomaterials change 
substantially after coming into contact with biological media. 
Such changes should be taken into consideration when exam-
ining the biological properties or environmental impact of 
nanoparticles.37 Based on these results, it is imperative to 
systematically evaluate the biocompatibility of Fe3O4@Au International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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composite MNPs and their toxicity within biological systems, 
especially in vivo, since results from in-vitro and in-vivo 
testing may be quite different.
A previous study reported the synthesis strategy 
involving a hetero-interparticle coalescence of molecu-
larly capped Au nanoparticles (2 nm) and iron-oxide 
nanoparticles (30–50 nm) as precursors in mixed solution, 
leading to core–shell nanoparticles. The results showed   
that gold   shell-coated Fe3O4-MNPs existed as aggregates 
with a broad size distribution, and the longest aggregate 
dimension varied from 100 nm to 2 µm. However, they 
exhibited improved biocompatibility in mammalian cells.32 
The strategy used in this present study involves sequential 
formation of the iron-oxide core and gold shell, and the 
composite particles were prepared by the reduction of Au3+ 
with hydroxylamine in the presence of Fe3O4-MNPs, with 
the average diameter of 20 nm as seeds. Compared with 
other reports,3,32 the Fe3O4@Au composite MNPs in this 
present study were proved to retain the quasi-spherical shape 
and uniform size by TEM and SEM. The results of laser 
particle size analysis illustrated that the average diameter 
of Fe3O4-MNPs was about 20 nm. After modification of 
the Fe3O4-MNPs with gold shell, the average diameter of 
the resulting core–shell Fe3O4@Au composite MNPs was 
about 35 nm, with a narrow diameter distribution. Thus, 
the thickness of the gold shell was estimated to be 7–8 nm. 
However, proper shell thickness is essential to obtain new 
optical properties and retain enough magnetism character-
istics for Fe3O4@Au composite MNPs. UV-vis spectra were 
therefore obtained to investigate the preparation and the 
optical properties of the self-prepared Fe3O4@Au composite 
MNPs. The UV-vis absorption spectra showed that Fe3O4-
MNP absorption spectra had no dramatic absorption in the 
visible region. However, after the Fe3O4-MNPs were coated 
with gold shell, 612 nm of the absorption peak was remark-
ably observed owing to the surface plasmon, indicating that 
the gold shell layer was formed on the surface of the Fe3O4 
core, consistent with the observation from other reports.3,4 
In contrast to the literature, the Fe3O4@Au composite 
MNPs in this present study had broader absorption spec-
tra and redshifted maximum absorption wavelength.3,38,39 
Such a redshift phenomenon of the plasmon absorption 
can be understood in terms of plasmon hybridization with 
the gold shell layer growth. In addition, because the gold 
shell layer outside the Fe3O4 core forms a rough surface 
after a coating of three iterations, strong interaction and 
coupling of the surface plasmon exists between neighboring 
nanoparticles, which may also contribute to the plasmon 
resonance redshift.40
Furthermore, the magnetic measurement showed that the 
Fe3O4@Au composite MNPs in this present study retained 
superparamagnetic properties with low coercivity and high 
Ms at room temperature, similar to Fe3O4-MNPs used in 
MFH.9 The Ms values of Fe3O4-MNPs and Fe3O4@Au com-
posite MNPs were estimated to be 75.5 and 51.8 emu/g, 
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respectively, which are much lower than that of bulk Fe3O4 
(Ms = 84 emu/g). Generally, the Ms decreased significantly 
when the gold shell formed on the surface of Fe3O4 MNPs. 
This reduction is expected as the surface magnetic order can 
be affected by structural distortions that cause spin canting.41 
However, the Ms of Fe3O4@Au composite MNPs is higher 
than that from other research.39,40 In addition, the detection 
of effective surface charge showed that the zeta potential of 
Fe3O4-MNPs was close to neutral charge (-3.6 ± 1.8 mV) 
at pH 7.4, the presence of gold shell shifted the zeta poten-
tial value to -23.2 ± 1.8 mV . A slightly high negative zeta 
potential imparted by Fe3O4@Au composite MNPs compared 
with Fe3O4-MNPs confirms an amount of gold coverage on 
the magnetite surface, which was in agreement with the 
literature.32
Next in this present study, the toxicity of self-prepared 
Fe3O4@Au composite MNPs was investigated through MTT 
assay, hemolysis test, MN assay, and acute toxicity testing 
in rodent and Canidae animals. The MTT assay is very 
often used to evaluate cell proliferation and the   viability for 
  biomaterial toxicity.13 In this present experiment, Fe3O4@Au 
composite MNPs with various concentrations of leaching 
liquor (100%, 75%, 50%, and 25%) were adjusted to test 
the cytotoxicity on L929 cells. The morphological obser-
vations showed that no significant toxic effects were seen 
compared with the negative control under the microscope, 
indicating that Fe3O4@Au composite MNPs have a minimal 
impact on the cell population as the cells remained viable 
and continued to proliferate. The toxicity of Fe3O4@Au 
composite MNPs was classified as grade 1, suggesting that 
they have good biocompatibility for cellular application, 
consistent with the literature, which reported negligible 
impact of Fe3O4@Au with amine functional group on 
mammalian cells.42
The hemolysis test is mainly used to evaluate the hemo-
compatibility of materials by detecting hemolyzation of 
erythrocytes. The erythrocyte membrane integrity may be 
destroyed by both mechanical injury of the particle surface 
and the chemical action of soluble remnant molecules, 
  resulting in hemolyzation when Fe3O4@Au composite MNPs 
Figure 9 Effect of Fe3O4@Au composite MNPs administered via liver injection on the tissue of beagle dogs after 4 weeks (hematoxylin-eosin staining, ×100 magnification). 
(A1) Little impact on the liver of the control group; (A2) Fe3O4@Au composite MNPs were taken up by cells around the needle passage in the liver of the experimental 
group, indicated by arrows; (B–F) no significant pathological changes were detected in the tissues including heart (B1 and B2), spleen (C1 and C2), lung (D1 and D2), 
kidney (E1 and E2), and brain (F1 and F2). 
Abbreviation: MNPs, magnetic nanoparticles.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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are used for thermotherapy. So the extent of hemolysis could 
be calculated by detecting the absorbance of released free 
hemoglobin using ultraviolet spectrophotometry.43,44 In this 
study, hemolysis rates at different concentrations of Fe3O4@
Au composite MNPs were all far less than 5%, which is the 
threshold for a hemolytic reaction, indicating that Fe3O4@
Au composite MNPs do not cause hemolysis and have good 
hemocompatibility, which is in agreement with previous 
studies.11,16
The short-term genetic toxicity was tested by MN 
assay, which is a rapid detection method of chromosome 
damage and interference with cell mitosis caused by the 
biological materials. If the result of this test is negative, it 
isn’t necessary to perform the carcinogenic test.45 Previ-
ously, Wu et al adopted the dosages of 5.00–1.25 g/kg to 
assess the short-term genetic toxicity of self-assembled 
Fe3O4-MNPs loaded with daunorubicin (DNR).16 In this 
study, the MN formation rates of experimental groups 
with different dosages from 5.00 to 1.25 g/kg showed no 
statistical difference compared with the negative control 
group, but a significant difference compared with the posi-
tive control group, suggesting Fe3O4@Au composite MNPs 
have no inherent toxicity to bone-marrow cells in mice. 
The results are similar to the MN assay of Fe3O4-MNPs 
and Fe3O4-MNPs loaded with DNR.11,16 Thus, it can be 
inferred that these nanoparticles do not induce cacogenesis 
or mutations.
The acute toxicity testing was used to evaluate short-
term toxicity after intraperitoneal administration in mice. 
In tumor thermotherapy, it is crucial to optimize dosing 
not only for effectively heating tumor tissue or promoting 
apoptosis of tumor cells, but also for reducing the systemic 
side effects. The LD50 of Fe3O4@Au composite MNPs 
administered by intraperitoneal injection was determined 
to be 8.39 g/kg in mice, and its 95% CI was found to fall in 
the range of 6.58–10.72 g/kg from the acute toxicological 
study. In contrast to Fe3O4-MNPs with the LD50 arriving at 
7.57 g/kg and Mn0.5Zn0.5Fe2O4-MNPs at 7.19 g/kg, Fe3O4@
Au composite MNPs have a wider safety margin.11,46 These 
parameters provide critical guidelines for the administration 
of this material in future studies.
Previous research of pharmacokinetics and tissue distri-
bution in mice showed that Fe3O4-MNPs were mostly taken 
up in the liver, suggesting the curative effect could be more 
pronounced for tumors in the liver.47 But the hepatotoxicity 
following gold salt therapy also has been previously reported, 
while accumulation of gold particles around hepatic veins, 
probably within macrophages, was observed, although no 
abnormal changes on the hematological parameters were 
observed.48 Therefore, investigated in this present paper was 
whether Fe3O4@Au composite MNPs could cause short-
term systemic toxic reactions during a 4-week period after 
liver injection in beagle dogs. The dosage of Fe3O4@Au 
composite MNPs via liver injection was 100 mg/kg, which 
was also adopted in the acute toxicological observations 
of Fe3O4-MNPs loaded with DNR.16 Typical toxicological 
responses such as slobbering, astasia, and anepithymia were 
not observed. Meanwhile, the body weights of the animals 
were measured every week, since body weight loss has 
been used as an indicator of adverse effects of drugs and 
chemicals.49 There was no significant difference in body 
weight of beagle dogs after administration of Fe3O4@Au 
composite MNPs compared with the control group. These 
results imply that liver injection of Fe3O4@Au composite 
MNPs made a negligible impact on the general behavior of 
beagle dogs. Moreover, the levels of ALT, AST, BUN, and 
Cr did not increase significantly when compared with those 
of the control group, suggesting that Fe3O4@Au composite 
MNPs did not cause both liver and kidney injury.
In addition, no abnormal changes of the hematological 
parameters were observed compared with the control group, 
showing that the lymphohemopoietic system was not affected 
by the Fe3O4@Au composite MNPs administered to the bea-
gle dogs. Furthermore, it was demonstrated that Fe3O4@Au 
composite MNPs did not induce lesions of organs and tissues 
by both autopsy study and histopathological investigation.
Meanwhile, it is noteworthy that Fe3O4@Au composite 
MNPs were almost ingested and deposited in the liver because 
no nanoparticles and hemosiderosis were observed in other 
organs including heart, spleen, lung, kidney, and brain, 
confirming the potential application in the intracellular and 
interstitial MFH combined with NIR hyperthermia on liver 
tumors with organ targeting and safety to biological systems 
in general. Thus, summarizing all the experimental results, 
it can be assumed that Fe3O4@Au composite MNPs do not 
cause any short-term systemic toxic reactions in beagle 
dogs with the dosage used in this study. In contrast to the 
investigation on the biocompatibility of magnetic albumin 
nanosphere (MAN) in a very recent publication, Fe3O4@Au 
MNPs indicate desirable biocompatibility in vivo at the high 
concentration of 100 mg/mL when MAN showed good bio-
compatibility at the concentration of 5 mg/mL in mice.50
Conclusion
In conclusion, the results of this study show that Fe3O4@Au 
composite MNPs appear to be highly biocompatible and safe International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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nanoparticles according to the evaluation of toxicity in vivo 
and in vitro. Considering that some of the Food and Drug 
Administration-approved MRI contrast agents are made of 
Fe3O4, Fe3O4@Au composite MNPs have a potential to be 
used as safe optical and thermal agents, allowing the combi-
nation of cancer detection and cancer-specific hyperthermic 
treatment. The results of this study provide experimental 
foundation for further clinical research and evaluation of this 
promising material.
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Biocompatibility of Fe3O4@Au composite
Table S1 Hematological values of beagle dogs in 4-week toxicity study of Fe3O4@Au composite MNPs
Group/parameter (units) WBC (×109/L) RBC (×1012/L) Hb (mg/mL) PLT (×109/L) Neu (×109/L) Lymp (×109/L)
Before administration
  Control 11.69 ± 1.80 7.17 ± 0.36 160.17 ± 14.73 298.83 ± 69.34 2.15 ± 1.47 9.00 ± 1.50
  Experimental 9.65 ± 2.23 7.23 ± 0.27 168.00 ± 10.24 355.00 ± 103.54 2.35 ± 1.52 7.04 ± 0.83
1 week after administration
  Control 11.45 ± 1.87 7.48 ± 0.44 171.00 ± 19.31 274.50 ± 43.08 2.50 ± 1.53 8.67 ± 0.70
  Experimental 11.61 ± 3.56 7.18 ± 0.32 167.67 ± 13.85 307.17 ± 88.05 2.38 ± 0.82 9.31 ± 3.11
2 weeks after administration
  Control 13.46 ± 2.04 7.52 ± 0.65 170.00 ± 21.82 240.67 ± 27.96 2.76 ± 2.03 10.06 ± 3.07
  Experimental 12.01 ± 2.50 7.52 ± 0.45 176.67 ± 12.50 340.83 ± 113.71 2.78 ± 1.66 8.66 ± 2.28
3 weeks after administration
  Control 10.88 ± 3.03 7.09 ± 0.86 161.33 ± 28.24 274.00 ± 53.23 2.61 ± 1.19 7.82 ± 2.14
  Experimental 14.20 ± 3.13 7.30 ± 0.43 171.67 ± 11.91 291.83 ± 60.71 2.81 ± 1.48 10.99 ± 3.09
4 weeks after administration
  Control 12.76 ± 1.79 7.15 ± 0.38 156.83 ± 19.95 261.67 ± 38.07 3.35 ± 1.55 8.57 ± 0.59
  Experimental 11.49 ± 2.04 7.11 ± 0.50 165.17 ± 10.87 322.17 ± 77.87 2.88 ± 1.09 7.95 ± 1.37
Notes: n = 6, mean ± standard deviation. There was no significant difference in hematological values of beagle dogs between the experimental group and the control group 
at the five time points of before administration and 1, 2, 3, and 4 weeks after administration of Fe3O4@Au composite MNPs (P . 0.05).
Abbreviations: MNPs, magnetic nanoparticles; WBC, white blood cells; RBC, red blood cells; Hb, hemoglobin concentration; PLT, platelets; Neu, neutrophils; Lymp, 
lymphocytes.
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